BTL to feature EXOMIND in WE tv segment on depression treatment

BTL will spotlight EXOMIND, its FDA-cleared noninvasive brain stimulation treatment for major depressive disorder, in a Life+Leisure segment airing Oct. 15 on WE tv. The episode aims to explain how the therapy works, reduce stigma around depression and show where it may fit alongside medication and talk therapy.

Why it matters: - Depression can be hard to treat, especially for adults who have not improved enough with antidepressant medication. - The WE tv segment is designed to show a non-drug option and encourage more people to talk with a healthcare provider about treatment choices. - EXOMIND adds to the conversation about noninvasive brain stimulation and how it may fit into mental health care.

What happened: - BTL will appear on Life+Leisure, hosted by Bill and Giuliana Rancic, in a WE tv segment airing Oct. 15, 2026, at 7:30 a.m. EST. - The segment features psychiatrist Dr. Michelle Dees discussing depression, TMS and EXOMIND. - Bill and Giuliana Rancic said people struggling with depression should know they are not alone and may have options they have not explored yet.

The details: - EXOMIND is an FDA-cleared, noninvasive treatment for major depressive disorder in adults who have not achieved satisfactory improvement from antidepressant medication during their current episode. - The treatment uses targeted magnetic pulses to stimulate the dorsolateral prefrontal cortex, a brain area involved in mood regulation. - EXOMIND requires no surgery or anesthesia and does not introduce medication into the body. - During treatment, patients remain awake and may feel a tapping sensation as pulses are delivered through an applicator placed against the head. - Sessions are outpatient, and patients can generally return to normal activities afterward. - The segment explains neuroplasticity, the brain’s ability to strengthen, reorganize and form new neural connections over time. - Repeated stimulation is intended to influence activity in brain networks associated with depression. - EXOMIND does not have to replace medication or talk therapy. - Depending on the patient and clinician guidance, TMS may be part of a broader treatment plan or considered for appropriate patients who have not improved enough with medication. - BTL was founded in the Czech Republic in 1993. - BTL’s technologies are distributed in 95 countries. - More than 600 research and development professionals work across BTL disciplines. - BTL says it has focused on long-term investment in medical innovation and has increased its emphasis on wellness, longevity and healthspan. - Learn more at BTL Healthcare and Life+Leisure.

Between the lines: - The segment pairs a medical device pitch with a stigma-reduction message, which broadens the appeal beyond patients already familiar with TMS. - BTL is positioning EXOMIND as part of a wider shift toward healthspan and mental well-being, not just treatment of symptoms. - The focus on a TV segment suggests BTL is trying to translate a clinical therapy into a more accessible consumer-facing story.

What's next: - Viewers can watch the full Life+Leisure segment on WE tv on Oct. 15, 2026, at 7:30 a.m. EST. - Patients interested in EXOMIND should consult a qualified healthcare provider to determine whether treatment is appropriate. - BTL is likely to continue linking EXOMIND with its broader noninvasive technology platform and wellness strategy.

The bottom line: - BTL is using national television to frame EXOMIND as a modern, non-drug option for some people with depression, while reinforcing the message that treatment choices are still evolving.